Stay updated on Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.

Latest updates to the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision: v3.5.2 was added and Revision: v3.5.0 was removed.SummaryDifference0.1%

- Check20 days agoChange DetectedThe study status was updated from Active, not recruiting to Completed, with revised completion/update dates.SummaryDifference0.5%

- Check34 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page now shows Revision: v3.4.3, replacing Revision: v3.4.2.SummaryDifference0.1%

- Check70 days agoChange DetectedPrimary completion and study completion are now estimated for 2026-12-31, and enrollment is updated to 24 participants. Recent update dates (2026-02-13 and 2026-02-17) were added and an older date (2026-02-28) was removed.SummaryDifference0.3%

- Check76 days agoChange DetectedRevision: v3.4.2 added; the prior funding-lapse notice (v3.4.1) was removed.SummaryDifference0.4%

Stay in the know with updates to Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Oral Azacitidine with Pembrolizumab in Metastatic Melanoma Clinical Trial page.